Related Experiment Video
Updated: Jan 31, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
ASCO 2018: highlights in HER2-positive metastatic breast cancer
Rupert Bartsch1,2, Elisabeth Bergen1,2
11Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Abstract:
At the 2018 ASCO Annual Meeting, data from several interesting studies in HER2-positive metastatic breast cancer were presented. While not immediately practice changing, these trials indicate the future directions of drug development in this field. Early phase studies with novel antibody-drug conjugates (ADCs) such as trastuzumab-deruxtecan and trastuzumab-duocarmazine suggest relevant clinical activity of these drugs in pretreated patients; in addition, these ADCs may offer activity in low HER2-expressing tumours as well. ZW25, a bispecific HER2-directed antibody targeting the extracellular domains 2 and 4, showed excellent tolerability and considerable single-agent activity. A combination of T‑DM1 with the tyrosine-kinase inhibitor neratinib yielded high response rates, while a study of trastuzumab plus durvalumab reported disappointing results. Although formally negative, overall survival data from the PHEREXA trial suggest clinical activity of dual HER2-inhibition with trastuzumab and pertuzumab in patients with prior trastuzumab treatment for advanced disease. A combined analysis of two tucatinib studies showed that systemic therapy is active when continued in case of isolated central nervous system progression and stable extracranial disease after local therapy of brain metastases; finally, a small prospective observation in asymptomatic patients with reduced left ventricular ejection fraction suggests that anti-HER2 treatment may be reasonably safe in this population.
Insights
Novel antibody-drug conjugates and bispecific antibodies show promise for HER2-positive metastatic breast cancer. Future research will focus on these agents and combination therapies for improved patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- HER2-positive metastatic breast cancer remains a significant clinical challenge.
- Advancements in targeted therapies are crucial for improving patient outcomes.
- Ongoing research explores novel agents and treatment strategies.
Purpose of the Study:
- To review emerging data on novel therapies for HER2-positive metastatic breast cancer presented at the 2018 ASCO Annual Meeting.
- To highlight potential future directions in drug development for this patient population.
Main Methods:
- Review of clinical trial data presented at the 2018 ASCO Annual Meeting.
- Focus on early-phase studies of antibody-drug conjugates (ADCs), bispecific antibodies, and combination therapies.
- Analysis of studies investigating treatments for pretreated patients and specific disease scenarios like CNS progression.
Main Results:
- Novel ADCs (trastuzumab-deruxtecan, trastuzumab-duocarmazine) show clinical activity in pretreated patients, potentially including low HER2-expressing tumors.
- ZW25, a bispecific HER2 antibody, demonstrated good tolerability and single-agent activity.
- Combination of T-DM1 with neratinib showed high response rates; trastuzumab plus durvalumab yielded disappointing results.
- PHEREXA trial suggests activity of dual HER2 inhibition (trastuzumab, pertuzumab) in previously treated advanced disease.
- Tucatinib studies indicate systemic therapy efficacy with isolated CNS progression and stable extracranial disease.
- Anti-HER2 treatment appears safe in asymptomatic patients with reduced ejection fraction.
Conclusions:
- Emerging antibody-drug conjugates and bispecific antibodies represent promising future directions for HER2-positive metastatic breast cancer.
- Combination strategies and continued systemic therapy in specific scenarios warrant further investigation.
- Careful patient selection and monitoring are essential for optimizing treatment outcomes.
Related Concept Videos
Position-effect Variegation
Chromatin Position Affects Gene Expression
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
Position and Displacement
Serial Position Effect
Position Vectors
For instance, we want to locate a point P(x, y, z) relative to the origin of coordinates O. In that case, we can define a position...
Anatomical Positions
The body is upright, facing forward, and standing erect.
The feet are parallel and flat on the floor.
The arms are hanging by the...

